With the increasing amount of available data, AI and machine learning have emerged as crucial tools for biopharmaceutical companies looking to remain competitive in the market. These tools are helping researchers speed up drug discovery, improve the clinical trial design and further personalize patient treatment.

Here are five areas where I see AI and machine learning changing the biopharmaceutical industry.

The unprecedented power of artificial intelligence (AI) is transforming the life sciences industry, opening doors to groundbreaking drug discoveries, innovative treatments and the promise of personalized medicine. As we harness AI's potential, addressing the ethical challenges that arise is imperative. This article outlines a new, robust ethical framework to ensure that AI serves humanity's best interests.

​

​

​

​

For 10 years, I have depended on Adderall to help me function. But in February, for the first time, the pharmacy down the street was unable to fill my prescription. In fact, 19 pharmacies in a row told me that they were out of stock. Thankfully, the 20th was able to fill it — though it meant a 50-minute drive.

​

​

​

​

​

​

​

Every organization faces operational inefficiencies that can impede productivity, hinder growth and waste resources. As a leader, it's your responsibility to identify these inefficiencies and streamline processes to make your organization more efficient and effective. However, identifying the biggest operational inefficiencies can be a challenge, especially if you don't know where to look.

​

​

​

​

​

A powerful movement is taking shape in the U.S. rare disease community that could transform the lives of millions of people. That’s right — millions. Even though a single rare disease may affect only a few individuals, there are several thousand of these problematic diseases that are difficult to identify and treat.

​

Since 2015, 21 U.S. states have passed legislation to create Rare Disease Advisory Councils that provide platforms for patients and family members to communicate with experts, policymakers, and the broader public. 

Invisible disabilities, as the name suggests, are disabilities that are not immediately apparent to others. Out of the 61 million adults in the United States who identify as having a disability of some kind, roughly 10% of those are invisible disabilities, which may include cognitive, neurological or mental health challenges.

​

I provide healthcare policy advice to Congress regarding disability policies, have led organizations that cater to individuals with disabilities and also have a disability myself.

​​

The Massachusetts Rare Disease Advisory Council (RDAC) is pleased to present its inaugural annual legislative report in accordance with the Acts of 2020 Chapter 260. The RDAC was established as part of Senate Bill 2984, An Act promoting a resilient healthcare system that puts patients first. The legislature enacted the bill in December 2020, signed into law by Governor Charlie Baker on January 1, 2021. This inaugural report describes the accomplishments of the RDAC over the past year.

​

​

​

I am here because the Affordable Care Act (ACA) saved my life. I was born and raised in Zacatecas, Mexico. When I was learning to walk as a child, like many kids, I would fall and bump my head. But in my case, when that happened, I’d start to bleed uncontrollably. My parents took me to the doctor, and I was diagnosed hemophilia. Hemophilia is a hereditary disorder that prevents a person’s blood from clotting. That means both internal and external bleeding can easily become life threatening

​

​

​